Salicylate-induced consumption coagulopathy.

Pinedo, H.M.; Putte, L B van de; Loeliger, E.A.

doi:10.1136/ard.32.1.66

Cited by 12 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coagulopathy has been reported in patients using salicylate and relevant publications are summarized in the supplemental table, which provides a summary of eight case reports and two case series [10][11][12][13][14][15][16][17][18]. All cases had eventual resolution of coagulopathy before either being discharged from the hospital or expiring.…”

Section: Discussionmentioning

confidence: 99%

“…Note that several of the reported cases involved salicylate-related coagulopathy in patients with normal hepatic function. One other published case involved bismuth subsalicylate [12], six publications involved acetylsalicylic acid [ 10,11,14,[16][17][18], and two publications involved methyl salicylate [13,15].…”

Section: Discussionmentioning

confidence: 99%

“…Of the cases with salicylate as the sole source of coagulopathy, three were found to have disseminated intravascular coagulation (DIC) based on findings of thrombocytopenia, increased prothrombin time, and increased fibrin split products [14,16,18]. Two of the three cases involved patients who already had transaminitis from disease-induced liver injury and developed DIC from further aggravation with aspirin use [16,18]. While the patient in the present case did not have thrombocytopenia, she had cirrhosis as preexisting liver disease, and DIC may have been a potential complication for her.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Bismuth Subsalicylate Coagulopathy in a Patient with Chronic Liver Disease

Eustaquio

Calello

et al. 2019

J. Med. Toxicol.

View full text Add to dashboard Cite

Bismuth subsalicylate (BSS) is the active ingredient in over-the-counter antacid and antidiarrheal medications. Coagulopathy in the setting of acetylsalicylic acid toxicity is well documented but not in setting of bismuth subsalicylate overuse. We present a case report of coagulopathy from BSS poisoning in a patient with underlying cirrhosis. The patient's high prothrombin time suggests inhibition of vitamin K-dependent coagulation factors. The patient had decreased factor V activity, which is responsible for converting prothrombin to thrombin. Patients with cirrhosis often have hypoprothrombinemia which may be exacerbated by salicylate-induced coagulopathy. Given the widespread use of BSS products, physicians should recognize coagulopathy as a possible manifestation of toxicity especially in patients with underlying liver disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bismuth Subsalicylate Coagulopathy in a Patient with Chronic Liver Disease

Eustaquio

Calello

et al. 2019

J. Med. Toxicol.

View full text Add to dashboard Cite

show abstract

Evidence for intravascular coagulation in systemic onset, but not polyarticular, juvenile rheumatoid arthritis

Scott

Gerber

Maryjowski

et al. 1985

Arthritis & Rheumatism

View full text Add to dashboard Cite

After observing a child with systemic onset juvenile rheumatoid arthritis (S-JRA) who developed purpura fulminans in association with disseminated intravascular coagulation, with subsequent gangrene and autoamputation, we undertook a prospective study of coagulation parameters in children with JRA. Ten consecutive children with S-JRA, 10 children with rheumatoid factor-negative, polyarticular juvenile rheumatoid arthritis (P-JRA), and 10 age-and sex-matched controls were studied. Routine coagulation screening tests were performed, as were tests for plasma fibrinopeptide A (a sensitive measure of intravascular thrombin generation), factor VIII-related antigen (an endothelial cell protein), and platelet factor 4 (a plateletsecreted protein). Our studies suggest that activation of intravascular coagulation is common in systemic onset JRA, but not in rheumatoid factor-negative, polyarticular disease. The coagulopathy may cause severe morbidity. In addition, marked elevations of plasma factor VIII-related antigen suggest perturbation of endothelial cells and vascular involvement in S-JRA, but not in P-JRA. Normal ranges of platelet factor 4 indicate that

show abstract

Juvenile Rheumatoid Arthritis

Jacobs

1993

Pediatric Rheumatology for the Practitioner

View full text Add to dashboard Cite

Child Heal&h and Develpment. 3rd ed. Edited by R. W. B. ELL-s. (Pp. ix-485; 93 figures-30 tables. 56s.) London: Churchill. 1962. This new edition of Professor Ellis's well-known book is published six years after the previous edition and much of the material is new. Part I covers normal development from conception to maturity. Part 1I is entitled-Social Aspects of Child Health' and includes chapters on the various child health services, education and juvenile courts. Normal biological values and legislation concerning children are the subjects of two appendices. The editor has assembled a team of 16 experts from widely differing fields to assist him in this work. Such names as Mildred Creak, Professor F. A. E. Crew

show abstract

Salicylate-induced consumption coagulopathy.

Cited by 12 publications

References 8 publications

Bismuth Subsalicylate Coagulopathy in a Patient with Chronic Liver Disease

Bismuth Subsalicylate Coagulopathy in a Patient with Chronic Liver Disease

Evidence for intravascular coagulation in systemic onset, but not polyarticular, juvenile rheumatoid arthritis

Juvenile Rheumatoid Arthritis

Contact Info

Product

Resources

About